Trametinib Dimethyl Sulfoxide

In this article, we will discuss Trametinib Dimethyl Sulfoxide (Dosage Overview). So, let’s get started.

Indications

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma

Trametinib is indicated, as a single agent in BRAF-inhibitor treatment-naïve patients or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or
V600K mutations, as detected by an FDA-approved test.

Adjuvant Treatment of BRAF V600E or V600K Mutation-Positive Melanoma

Trametinib is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

BRAF V600E Mutation-Positive Metastatic NSCLC

Trametinib is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.

BRAF V600E Mutation-Positive Locally Advanced or Metastatic Anaplastic Thyroid Cancer

Trametinib is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.

Dosage

Patient Selection

Melanoma

Confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment with Trametinib as a single agent or in combination with dabrafenib.

NSCLC
Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with Trametinib and dabrafenib.

ATC

Confirm the presence of BRAF V600E mutation in tumor specimens prior to initiation of treatment with Trametinib and dabrafenib. An FDA-approved test for the detection of BRAF V600E mutation in ATC is not currently available.

Recommended Dosage for Unresectable or Metastatic Melanoma

The recommended dosage of Trametinib is 2 mg orally taken once daily, as a single agent or in combination with dabrafenib, until disease progression or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information

Recommended Dosage for the Adjuvant Treatment of Melanoma

The recommended dosage of Trametinib is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity for up to 1 year. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.

Recommended Dosage for NSCLC

The recommended dosage of Trametinib is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.

Recommended Dosage for ATC

The recommended dosage of Trametinib is 2 mg orally taken once daily in combination with dabrafenib until disease recurrence or unacceptable toxicity. Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.